Antibodies
6 October 2008
Roche announces topline outcomes for Avastin-Tarceva combination study in advanced lung cancer6 October 2008
Novo Nordisk and Innate Pharma swap product rights5 October 2008
Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient5 October 2008
Genentech, Glycart and Roche enter into collaboration agreement for potential cancer therapy2 October 2008
Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US2 October 2008
Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy2 October 2008
Access Pharmaceuticals Presents New Data on the Company’s Angiolix(R) Therapeutic Monoclonal Antibody2 October 2008
Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation30 September 2008
Antisoma starts phase II trial of AS1402 in breast cancer30 September 2008
Phase 2 Study of IMC-1121B for Advanced Ovarian Cancer Commences Patient Enrollment29 September 2008
VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting25 September 2008
Randomized Phase 2 Study of IMC-A12 for Advanced Breast Cancer Commences Patient Enrollment24 September 2008
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop23 September 2008
AVEO Initiates First Clinical Trial of Novel HGF Antagonist23 September 2008
ERBITUX(R) Five-Year Data Show Significant Improvement in Overall Survival for Patients with Locally or Regionally Advanced Head and Neck Cancer22 September 2008
Maxygen and Astellas Announce Global Agreement to Develop New Therapies for Autoimmune Diseases and Transplantation22 September 2008
Recruitment Completed In Ofatumumab NHL Front Line Study21 September 2008
FDA issues complete response letter to Roche for Actemra Biologics License Application16 September 2008
Merck KGaA: New First-Line Data Demonstrate Response Rates of Up to 80% for Erbitux in KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)16 September 2008
New Programs Added in Antibody Collaboration Between XOMA and TakedaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports